Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 13, 2021 at 09:05 pm
Share
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 499.832 million compared to TWD 391.913 million a year ago. Operating income was TWD 149.352 million compared to TWD 87.431 million a year ago. Net income was TWD 126.329 million compared to TWD 371.148 million a year ago. Basic earnings per share was TWD 1.63 compared to TWD 4.79 a year ago. Diluted earnings per share was TWD 1.62 compared to TWD 4.78 a year ago. For the half year, sales was TWD 921.442 million compared to TWD 699.352 million a year ago. Operating income was TWD 258.919 million compared to TWD 114.938 million a year ago. Net income was TWD 224.576 million compared to TWD 398.903 million a year ago. Basic earnings per share was TWD 2.9 compared to TWD 5.14 a year ago. Diluted earnings per share was TWD 2.88 compared to TWD 5.12 a year ago.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
